Introduction
Monitoring of engraftment by assessing chimerism is currently performed after allogeneic bone marrow transplantation (BMT). Two main approaches are generally used for this purpose: fluorescent in situ hybridization (FISH) and in vitro amplification (PCR) of polymorphic sequences. FISH has the advantage of giving quantitative results, but its application is restricted to cases with a sex-mismatched donor. PCR analysis of polymorphic markers has a more general applicability. Given their high degree of polymorphism and the simplicity of their analysis, markers such as minisatellites and microsatellites are the more appropriate targets. 1 PCR is not a technique that is readily quantitative. However, coupling PCR to the use of a fluorescence DNA analyzer permits accurate measurement of the amount of PCR product and development of quantitative strategies. 2, 3 Techniques used for chimerism assessment are generally homemade and vary from one laboratoy to another. This heterogeneity makes the comparison of results difficult and hinders the emergence of a consensus on a general strategy for chimerism monitoring. As a contribution to the debate engaged in Leukemia, 4, 5 we describe here the technique adopted in our laboratory and we report results obtained for 60 patients who underwent allogeneic BMT in our institution.
I. Assay characteristics
The method used was based on the discrimination of donor and recipient alleles using STR (short tandem repeat) PCR. STRs express a high degree of size polymorphism, thus giving rise to PCR products of various lengths. PCR was performed using primers labeled with fluorescent dyes. After amplification, separation of the PCR products and fluorescence detection were achieved by migration on a capillary electrophoresis instrument. In an initial screening to find informative loci (ie for which at least one allele of the recipient differs from those of the donor), six different STR markers were systematically amplified by PCR. Assessment of donor chimerism was based on the calculation of the ratio of signals obtained for one informative recipient allele to that obtained for one donor allele. When recipient's alleles were not detected in a post-BMT sample, low dilutions of recipient in donor DNA were systematically tested to determine the sensitivity of the detection. When recipient alleles were still detected in a post-BMT sample, chimerism was quantitated using a standard curve constructed from known dilutions of recipient in donor DNA.
II. Protocol

DNA preparation
DNA was obtained from total leukocytes using standard phenol/chloroform extraction, and spectrophotometrically quantitated. Accurate DNA quantitation is an essential step because it determines the reliability of the recipient/donor dilutions used for standard curves and for sensitivity assessment. After quantitation, DNA was diluted to a final concentration of 100 ng/l in 10 mM Tris-1 mM EDTA (TE) buffer.
PCR amplification
Six STR markers were systematically amplified in the donor and the recipient prior to transplantation, in order to determine their STR profiles and to choose a suitable marker. STR characteristics are given in Table 2 . All markers were amplified under identical PCR conditions. PCR reactions were set up separately in a final volume of 25 l containing 0.2 M of each primer, 200 M dNTP, 1 × Gene amp PCR buffer II (Applied Biosystems, Roissy, France), 2.5 mM MgCl 2 , 0.625 U of AmpliTaq Gold (Applied Biosystems) and 1 l (100 ng) of template DNA. To save time and improve reproducibility, pre-mix containing all reagents except the Taq polymerase were prepared for 100 tests for each marker, aliquoted and stored at −20°C until used. Taq polymerase was then added in a volume of 10 l distilled water. PCR was carried on in a Kontron UNO-Thermoblock (Biometra, Gö ttingen, Germany) having a ramping time of 1°C/s. After an initial incubation step at 95°C for 10 min to activate the hot-start Taq polymerase, 35 cycles were performed using the following profile: denaturation at 95°C for 10 s, annealing at 50°C for 10 s, with a final elongation step at 72°C for 2 min. Primer sets chosen enabled either 0% or 100% generation of 'A' overhangs to be obtained under these PCR conditions. This is important for avoiding formation of double peaks that might reduce sensitivity. After PCR, the samples were stored at 4°C in the dark until electrophoresis.
Analysis of PCR products
PCR products were analyzed by capillary electrophoresis on an ABI Prism 310 Genetic Analyzer (Applied Biosystems), using the POP-4 polymer, the 'green' 47 cm capillary and the 10 × 310 GA Buffer with EDTA. A 1.5 l portion of the PCR reaction was mixed with 12 l of deionized formamide containing 0.5 l Genescan TAMRA 350 size standard (Applied Biosystems). Samples were denatured at 95°C for 3 min and chilled for at least 3 min in an ice-water bath. After placing the specimens in the sample rack, standard injection parameters were programmed. In certain cases, the loading of increasing amounts of PCR product permitted improvement of sensitivity.
After electrophoresis, each allele gave rise to a major peak, the size of which depends on the number of nucleotide repeats, associated with smaller, less intense products or 'stutter bands'. PCR products were sized, and areas under the peaks were determined using the 310 Genescan (Applied Biosystems) integration software.
Allelic patterns obtained for donor and recipient were compared in order to detect the STR providing the more convenient configuration. Recipient alleles were considered informative if their size was distinguishable from both the major peaks and the stutter bands corresponding to the donor's alleles. When several informative STRs were found, the following configurations were chosen in priority: (1) at least one recipient-specific allele smaller than the donor alleles, (2) homozygosity of recipient alleles. To get a rapid overview of the engraftment, the first post-BMT sample was usually analyzed together with the donor and recipient pre-BMT samples in this first screening process, while only the STR displaying the optimal configuration was used for chimerism assessment in the following post-BMT samples.
Alleles that differed between recipient and donor were then identified in post-transplant samples, according to their size. If no peak corresponding to informative recipient alleles was detected in the post-transplantation sample, the sensitivity of the detection was assessed. Alternatively, if recipient alleles were still detected, quantitation was achieved.
Assessment of detection sensitivity
The absence of detection of recipient alleles does not mean that no more hematopoietic cells from the recipient persist but that their level is below the detection threshold. Because the sensitivity varies according to the allelic configurations of the STRs, we determined detection threshold for each recipient/donor couple in case of negative result. For this purpose, 5%, 2.5% and/or 1% dilutions of recipient in donor DNA were systematically tested along with the post-BMT sample, using the STR expected to give the best sensitivity as anticipated from its allelic configuration.
Quantitation of donor chimerism
When recipient alleles were still detected after transplantation, quantitation was performed using one STR that displayed an informative recipient allele (ie the size of which was distinct from both the major peaks and the stutter bands of donor alleles). Standard curves were constructed for each patient by amplifying in the same experiment serial dilutions of pretransplant DNA in donor DNA. The ratio of peak height of one recipient-specific allele to one donor-specific allele was calculated for each sample. A standard curve was drawn that gave the relationship between the allelic ratio and the percentage of recipient DNA. The percentage of chimerism in the post-BMT sample was determined from the ratio obtained, using the calibration curve ( Figure 1 ).
Figure 1
Quantitative assessment of chimerism using marker D8S285. Initial screening showed that the 106 base allele was recipient specific. Major peaks corresponding to alleles were darkened. The ratio of peak heights of alleles 106 to allele 102 was measured in the post-BMT sample and in serial dilutions of recipient in donor DNA. A standard curve was then drawn that gave the correspondence between the allelic ratio and the percentage of recipient cells in the sample. Entering the ratio found for the post-BMT sample on this standard curve indicated that it contained 35% recipient cells. The time indicated represents the minimum time requirement for complete processing of the sample from its reception to the final result. It might be reduced using other types of sequence analyzers.
IV. Specificity/informativeness
Sixty cases were prospectively analyzed using six STRs. Recipient and donor allelic patterns could be identified unambiguously for one or more STR in all cases. In agreement with Thiede et al, 6 we found that co-migration with stutter bands hampered sensitive detection and quantitation of chimerism. Thus, we considered that recipient alleles co-migrating with the stutter band of donor alleles were non-informative. The median number of STRs per patient with at least one informative recipient allele was between three and four. The number of STRs that displayed both a recipient-specific and a donorspecific allele was slightly lower, with a median between two and three. In one case, because of co-migration of the recipient allele with the stutter band of a donor allele no STR displayed a pattern with a distinguishable allele for both the donor and recipient. However, although the absence of donor-specific alleles has been reported to hamper the accuracy of the quantitation, 6 it was not the case in our hands. This difference is probably due to the fact that, in our assay, quantitation is achieved by comparison with a standard curve analyzed in the same experiment, which exactly mimics the sample to be quantitated. Thus, in our experience, the presence of at least one recipient-specific allele was the only prerequisite for a marker to be suitable for chimerism assessment.
As expected, the number of informative STR was higher in cases with an unrelated donor than in cases with a related donor.
V. Sensitivity
Sensitivity was determined in 54 cases by testing dilutions of recipient in donor DNA. The detection sensitivity was 1% in 12 cases (22%), 2.5% in 34 cases (63%), 5% in seven cases (13%) and 10% in one case (2%). Sensitivity assessment was repeated when analyzing a new sample and was found highly reproducible. No difference in sensitivity was observed according to the type of STR (tetra-vs di-nucleotide repeat). Cases in which at least one recipient allele was shorter than donor alleles tended to display a better sensitivity, and 85% of STRs giving 1% sensitivity displayed this configuration. This is due to the fact that PCR efficacy is higher for shorter sequences. Therefore, for a large majority of STRs, the signal ratio of the smaller to the longer allele is higher than 1. This preferential amplification of short sequences can be used to increase the sensitivity of the detection by choosing STRs in which recipient alleles are shorter than the donor ones.
VI. Reproducibility
Intra-manipulation variations were less than 5%. Twelve positive samples were analyzed twice in separate manipulations, Leukemia sometimes separated by several months. Inter-manipulation variation was below 10% in 11 out of 12 samples and 30% in one sample (mean 7%). To improve the reliability of kinetic evaluation, in the case of positive chimerism the previous follow-up sample was generally re-analyzed together with the current one.
VII. Cost
Cost of consumables is about 30 Euros for analysis of the first sample (including screening process), and 5.5 Euros for the following samples. Cost calculation includes the systematic checking of the assay sensitivity.
VIII. Technical discussion
An increasing number of chimerism studies use quantitative assessment. Some studies use quantitation by comparison to a standard curve constructed from dilutions of recipient DNA in donor DNA. 7 Quantitation by direct measurement of the signal ratio of one recipient-specific allele to the sum of signals of the donor and recipient alleles has also been proposed. [4] [5] [6] This strategy requires the availability of at least one STR displaying both a recipient-and a donor-specific allele. 6 This requirement, which is not necessary when using a standard curve, might increase the number of STR needed for screening. More importantly, this strategy is based on the assumption that all alleles amplify with the same efficiency. If so, each allele behaves as a homologous competitor for others and accurate quantitation can be achieved as described for competitive PCR. 8 In our experience, as mentioned above, a great majority of STR displays a preferential amplification of the shorter allele. Thus, the ratio of their PCR products does not provide a direct measure of the ratio of allele copy numbers, especially when differences in allelic sizes are large. We applied the calculation of donor chimerism described by Thiede et al 6 to four series of recipient/donor dilutions. Recipient and donor shared no common allele in two cases and one allele in two cases. Values obtained for donor chimerism were identical to theoretical ones in one case but highly underestimated in three cases in which one of the recipient alleles was 8 to 20 bases shorter than the donor allele(s). Underestimation was more than 200% in the case with a 20 base difference in size. This shows that such a calculation may not be reliable for all STRs, and attention must be paid to the relative amplification efficacy of alleles, particularly for STRs with a high variability in size. For these reasons, we favored the use of individual standard curves to quantitate chimerism, although this strategy can appear more cumbersome.
IX. Clinical application
Patients
Sixty children undergoing allogeneic bone marrow transplantation were studied between November 1997 and May 2001. The donor was an HLA-matched or haploidentical relative in 29 cases and HLA-matched unrelated in 31 cases. Underlying diseases were diverse in this pediatric series. Patient details and conditioning regimen are given in Table 1 . All patients received unmanipulated marrow grafts. Post-transplant GVHD prophylaxis was uniform, using cyclosporin A and methotrexate.
For chimerism analysis, 5 ml of blood was collected on EDTA from the donor and the recipient prior to transplantation, and from the recipient at different time points after transplantation.
Post-transplantation chimerism in patients
Sixty patients were prospectively studied for post-transplantation chimerism at various time points. Two patients failed to engraft. In these two patients, donor cells were transiently detected at day 15 after transplantation at levels close to 60% and then disappeared. Thirty-two patients had chimerism determination at days 30-40 after BMT. At this time point, recipient cells were undetected or Ͻ2.5% in 20 patients (62%), while they ranged from 2.5% to 10% in 12 patients (38%). The five patients who suffered early graft rejection (n = 2) or relapse (n = 3) displayed 5 to 10% of recipient cells at this time point. One of these patients, who was initially treated for AML received an injection of donor lymphocytes Table 1 Clinical data of the 60 patients prospectively studied for chimerism
Disease
Conditioning regimen Malignant (n = 43) Acute (DLI) at day 39 that permitted restoration of engraftment. Recipient cells decreased very rapidly after DLI, became undetectable (Ͻ1%) 6 months after BMT, and were still undetectable after 2 years (Figure 2) . Seven other patients, including one with AML displayed 2.5 to 5% of recipient cells at days 30-40 without any clinical consequence. These results show that although children who will suffer graft rejection all have a high percentage of recipient cells at this time point, there is a marked overlap of chimerism values with a group of children who have a good prognosis. When performed, chimerism detection at earlier time points was even less discriminant. However, at later time points, the percentage of donor chimerism decreased very rapidly in children who eventually suffered graft rejection, while it remained stable or increased in the others. Thus, only the kinetics of chimerism distinguished these two populations of children. Some studies have suggested that investigation of specific leukocyte subsets provides insight into immunologic processes indicative of graft rejection and/or relapse. 6, [9] [10] [11] Such an analysis could be proposed in situations where persistence of overall chimerism is observed, in order to identify more rapidly impending rejection or relapse in this group of patients. However, very few data are available concerning leukocyte subset trends in nontumoral patients.
Long-term persistence of chimerism
Long-term persistence of detectable recipient cells was observed in eight patients. In these patients, stable rates of 2.5% to 25% of recipient cells were detected over periods of 4 months to 3 years ( Figure 3 ). All these patients had nontumoral underlying disease (three cases of sickle cell disease, three aplastic anemia, one hystiocytosis and one Fanconi anemia), and the donor was always an HLA-matched relative. Such a persistence of chimerism has not been observed in other studies using STR analysis 9 but the level of residual recipient cells was Յ5% in five of these patients and could have remained undetected in studies using a less sensitive detection method. Besides, this observation might be related to the type of conditioning regimen, which in our study did not include total body irradiation for patients with non-tumoral disease. It might also be related to the type of donor because none of the five patients with non-tumoral disease who had an unrelated donor displayed such a persistence. This observation demonstrates that, in a context of non-tumoral disease, the persistence of detectable recipient cells, even at relatively high levels, is not necessarily predictive of an impending graft rejection.
In conclusion, sequential follow-up, which provides kinetic information appears more relevant than one-point chimerism determinations. However, the optimal timing of chimerism analysis has still to be determined and might differ according to the underlying disease and to the type of transplantation and conditioning regimen. All these parameters are generally very heterogeneous both in and between institutions. The small size of each sub-group of patients in each report makes the establishement of guidelines for chimerism assessment difficult. Therefore, we think that standardization of methods and of sampling time points is a major goal that should permit comparison of patients treated in different institutions, and, finally, optimization of the clinical use of chimerism monitoring. [12] [13] [14] [15] [16] [17] 
